Politico, June 15, 2021: The controversial approval of the first drug to target Alzheimer’s disease in nearly 20 years has been blasted by many experts, because the drug is not proven to work and will cost $56,000 per year. “You don’t have to be a rocket scientist to know that the impact on Medicare is likely to be devastating,” said Diana Zuckerman, the president of the National Center for Health Research.
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
Alzheimer’s drug approval debacle deepens FDA scrutiny
Politico, June 11, 2021: Dr. Diana Zuckerman speaks with Politico on the impact that the newly approved Alzheimer’s drug will have on Democratic senators.
Read More »Teens are worried about wrinkles. Here’s how Gen Z is helping to fuel a beauty boom
CNN, May 6, 2021: While teens are increasingly spending time and money to prevent wrinkles, experts are concerned about the premature demand for more invasive treatments.
Read More »Biden’s ‘end cancer’ pledge begs for environmental oversight
E&E News, May 4, 2021: President Biden pledged last week to “end cancer as we know it,” a bold promise focused on boosting funding to the National Institutes of Health for a special Advanced Research Projects Agency-Health. But public health experts who have spent their careers examining environmental causes of cancer say it may not be possible to truly stop cancer without EPA stepping in.
Read More »To Stay: Two More Cancer Indications With ‘Dangling Approvals’
Medscape News, April 29, 2021: Two more cancer indications that had been granted accelerated approval by the US Food and Drug Administration (FDA) are going to stay in place, at least for now. This was the verdict after the second day of a historic 3-day meeting (April 27–29) and follows a similar verdict from day one.
Read More »